Another company IPO filing has been on Monday from Cellular Dynamics International, Inc. No financial terms have been set, but the filing is for up to $57,250,000 worth of common sock. The company has applied to have its common stock listed on the NASDAQ Global Market under the symbol “ICEL.” The sole book–running manager is J.P. Morgan and co-managers include the firms Cowen & Company and Leerink Swann.

Cellular Dynamics develops fully functioning human cells in industrial quantities to precise specifications. Its proprietary iCell Operating System includes true human cells in multiple cell types and human induced pluripotent stem cells. Its products provide standardized and cost-effective access to the human cell for drug discovery and screening. Other uses include testing the safety and efficacy of their small molecule and biologic drug candidates, stem cell banking, and in researching cellular therapeutics.

The company’s customers include biotech companies, government research institutions, academic and nonprofit research institutions, clinical research organizations and stem cell banks. During 2012, the company claims to have sold its products to 18 of the top 20 biopharmaceutical companies based on worldwide revenue. It also grew its number of clients to 128 in 2012 from just 60 in 2011.

Revenue in the year 2011 was $1.46 million and that grew to $5.178 million in 2012. Sales in the first three months of 2012 were $643,000 but that grew to $1.754 million for the first three months of 2013.

FULL S-1 SEC FILING

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.